西布曲明对超重及单纯性肥胖患者血浆神经肽Y水平的影响

EFFECTS OF SIBUTRAMINE ON PLASMA NEUROPEPTIDE Y LEVELS IN PATIENTS WITH OVERWEIGHT AND SIMPLE OBESITY

为研究超重和单纯性肥胖患者空腹血浆神经肽Y(NPY)水平 ,探讨减肥药物———西布曲明对其的影响。 32名超重和单纯性肥胖患者被随机、双盲地分为西布曲明组(A组 )、安慰剂组 (B组) ,16名健康者作为对照组 (C组 ) ,采用放免法测定治疗 6月前后患者空腹NPY、胰岛素水平。结果显示 ,治疗前A、B两组NPY水平明显高于C组 ;治疗后A、B两组NPY水平与治疗前相比差异不显著。提示超重和单纯性肥胖患者空腹NPY水平升高 ;西布曲明对超重和单纯性肥胖患者空腹NPY水平无影响。

The aim of the study was to evaluate the effects of an anti obese agent, sibutramine, on plasma neuropeptide Y(NPY) levels in patients with overweight and simple obesity. 32 patients with overweight and simple obesity were assigned randomly to sibutramine group (group A) or placebo group (group B). Double blind rule was observed in the study. 16 healthy subjects served as control group (group C). Before and after six months of treatment, plasma NPY and serum insulin levels of patients in both groups were measured with radioimmunoassay (RIA). The results showed that fasting plasma NPY levels were higher in obese group than in control group before treatment .No significant difference was found between plasma NPY levels before and after the treatment with sibutramine. The study revealed that patients with overweight and simple obesity had elevated levels of plasma NPY. Sibutramine did not exert any influence on plasma NPY levels in these patients.